𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant imatinib therapy for gastrointestinal stromal tumors

✍ Scribed by Peter W.T. Pisters; Chiara Colombo

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
82 KB
Volume
104
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Imatinib as adjuvant therapy for gastroi
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review
✍ Munira Essat; Katy Cooper πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 266 KB πŸ‘ 1 views

## Abstract The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)‐positive resected GIST. Relevant studies

Systemic therapy for advanced gastrointe
Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib
✍ Edward J. Kim; Mark M. Zalupski πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## Abstract Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR

Adjuvant and neoadjuvant imatinib therap
Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors
✍ Burton L. Eisenberg; Jonathan C. Trent πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 212 KB

## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off

Novel V600E BRAF mutations in imatinib-n
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
✍ Narasimhan P. Agaram; Grace C. Wong; Tianhua Guo; Robert G. Maki; Samuel Singer; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 462 KB

## Abstract __BRAF__ and __NRAS__ are commonly mutated in cancer and represent the most frequent genetic events in malignant melanoma. More recently, a subset of melanomas was shown to overexpress KIT and harbor __KIT__ mutations. Although most gastrointestinal stromal tumors (GISTs) exhibit activa